Geometry Dash APK Hill Climb Racing APK
65.5 F
New York
Saturday, September 30, 2023

Is the Rough Ride Over for Hepion Pharmaceuticals Inc. (HEPA)

Must read

Hepion Pharmaceuticals Inc. (HEPA) shares are trading at lower $1.58 and the avg recommendation for the stock is Moderate Buy.

To add more color to this target, the company’s high over the last year is $8.35 and the low is $1.00. Over the last 52 weeks, HEPA is down -65.80% while the S&P 500 is up 15.47%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, HEPA reported a profit of $16000.0. Hepion Pharmaceuticals Inc. also saw revenues increase to $6.23 million. In addition, HEPA has free cash flow of -$11.65 million as of 09-2020. The company’s EBITDA came in at -$6.22 million which compares well with its peers.

HEPA Return on Equity (ROE) is -116.80%, and its Return on Assets is -78.50%. All told, it is clear that, HEPA needs to be on your watchlist.

Find out when HEPA reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. HEPA has a short ratio of 1.00 and outstanding shares of 9.03M.

Company Outlook

HEPA has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.6 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -2.61. Hepion Pharmaceuticals Inc. HEPA also noted assets of $20.36 million at the end of the last quarter. Investors should also keep an eye on sector updates as HEPA has historically followed its peers on positive news.

All told, Hepion Pharmaceuticals Inc. HEPA has strung together solid data and demonstrated underlying fundamentals. At its current valuation, HEPA represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Hepion Pharmaceuticals Inc. HEPA is now commanding a market cap of 14.38M and a float of 8.97M. HEPA is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of HEPA stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in HEPA, either long or short, and we have not been compensated for this article.

Latest article